Logo image of GLTO

GALECTO INC (GLTO) Stock Fundamental Analysis

NASDAQ:GLTO - Nasdaq - US36322Q2066 - Common Stock - Currency: USD

2.96  -0.1 (-3.27%)

After market: 3.0186 +0.06 (+1.98%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GLTO. GLTO was compared to 561 industry peers in the Biotechnology industry. GLTO has a great financial health rating, but its profitability evaluates not so good. GLTO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GLTO had negative earnings in the past year.
In the past year GLTO has reported a negative cash flow from operations.
GLTO had negative earnings in each of the past 5 years.
In the past 5 years GLTO always reported negative operating cash flow.
GLTO Yearly Net Income VS EBIT VS OCF VS FCFGLTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -125.14%, GLTO is doing worse than 80.93% of the companies in the same industry.
GLTO's Return On Equity of -135.42% is on the low side compared to the rest of the industry. GLTO is outperformed by 61.68% of its industry peers.
Industry RankSector Rank
ROA -125.14%
ROE -135.42%
ROIC N/A
ROA(3y)-103.21%
ROA(5y)-74.46%
ROE(3y)-117.92%
ROE(5y)-83.79%
ROIC(3y)N/A
ROIC(5y)N/A
GLTO Yearly ROA, ROE, ROICGLTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

GLTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLTO Yearly Profit, Operating, Gross MarginsGLTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

GLTO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GLTO has less shares outstanding
There is no outstanding debt for GLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GLTO Yearly Shares OutstandingGLTO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GLTO Yearly Total Debt VS Total AssetsGLTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

GLTO has an Altman-Z score of -22.98. This is a bad value and indicates that GLTO is not financially healthy and even has some risk of bankruptcy.
GLTO's Altman-Z score of -22.98 is on the low side compared to the rest of the industry. GLTO is outperformed by 88.77% of its industry peers.
There is no outstanding debt for GLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.98
ROIC/WACCN/A
WACCN/A
GLTO Yearly LT Debt VS Equity VS FCFGLTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

GLTO has a Current Ratio of 14.07. This indicates that GLTO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 14.07, GLTO belongs to the top of the industry, outperforming 87.17% of the companies in the same industry.
A Quick Ratio of 14.07 indicates that GLTO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 14.07, GLTO belongs to the best of the industry, outperforming 87.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.07
Quick Ratio 14.07
GLTO Yearly Current Assets VS Current LiabilitesGLTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.73% over the past year.
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GLTO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.23% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.06%
EPS Next 2Y-6.16%
EPS Next 3Y-20.18%
EPS Next 5Y15.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLTO Yearly Revenue VS EstimatesGLTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2030 10M 20M 30M
GLTO Yearly EPS VS EstimatesGLTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GLTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLTO Price Earnings VS Forward Price EarningsGLTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLTO Per share dataGLTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 -15

4.3 Compensation for Growth

GLTO's earnings are expected to decrease with -20.18% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.16%
EPS Next 3Y-20.18%

More info and screens

0

5. Dividend

5.1 Amount

GLTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALECTO INC

NASDAQ:GLTO (5/21/2025, 8:00:37 PM)

After market: 3.0186 +0.06 (+1.98%)

2.96

-0.1 (-3.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01
Earnings (Next)08-11 2025-08-11
Inst Owners13.05%
Inst Owner Change0.25%
Ins Owners3.61%
Ins Owner Change0.1%
Market Cap3.91M
Analysts82.5
Price Target8.16 (175.68%)
Short Float %5.48%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-26.84%
Min EPS beat(2)-72.64%
Max EPS beat(2)18.96%
EPS beat(4)3
Avg EPS beat(4)12.17%
Min EPS beat(4)-72.64%
Max EPS beat(4)52.18%
EPS beat(8)7
Avg EPS beat(8)20.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-7.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.25
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-17.62
EYN/A
EPS(NY)-14.79
Fwd EYN/A
FCF(TTM)-14.11
FCFYN/A
OCF(TTM)-14.11
OCFYN/A
SpS0
BVpS11.99
TBVpS11.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.14%
ROE -135.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.21%
ROA(5y)-74.46%
ROE(3y)-117.92%
ROE(5y)-83.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.07
Quick Ratio 14.07
Altman-Z -22.98
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.83%
EPS Next Y16.06%
EPS Next 2Y-6.16%
EPS Next 3Y-20.18%
EPS Next 5Y15.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-223.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.55%
OCF growth 3YN/A
OCF growth 5YN/A